Quantum BioPharma Makes Strategic Investment in GameStop Corp.
Rhea-AI Summary
Quantum BioPharma (NASDAQ: QNTM) has announced a strategic investment in GameStop Corp. (NYSE: GME), purchasing 2,000 shares. This move is part of the company's broader strategy to combat market corruption and enhance shareholder value. The company has recently appointed anti-market manipulation advocates including Kevin Malone as Board Advisor and Terry Lynch as Director.
The company is pursuing legal action against CIBC World Markets and RBC Dominion Securities, seeking damages exceeding $700 million USD for alleged stock manipulation. Additionally, Quantum completed a debt settlement of US$40,000 through the issuance of Class B shares. Malone Wealth Ventures, LLC, which owns approximately 21.8% of Quantum's Class B shares, received 30,000 shares and 60,000 RSUs as consulting compensation.
Positive
- None.
Negative
- Significant share dilution through consulting compensation and debt settlement
- Deviation from core business focus on neurodegenerative therapies with GameStop investment
- Large ownership concentration with Malone Wealth Ventures holding 21.8% of Class B shares
News Market Reaction – QNTM
On the day this news was published, QNTM declined 7.80%, reflecting a notable negative market reaction. Argus tracked a trough of -13.1% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $69M at that time.
Data tracked by StockTitan Argus on the day of publication.
TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for neurodegenerative disorders, today announced the purchase of 2,000 shares of GameStop Corp. (NYSE: GME) to hold on the Company's balance sheet as a strategic investment. This move aligns with Quantum BioPharma's ongoing commitment to combating market corruption and enhancing shareholder value through prudent financial strategies and advocacy against manipulative trading practices.
The Company has been at the forefront of fighting market corruption, as evidenced by its recent appointments of advocates like Board Advisor Kevin Malone (see PR April 22, 2025) and Director Terry Lynch (see PR March 27, 2025), both known for their crusades against naked short selling and stock manipulation. Mr. Malone is the Chief Executive Officer and sole owner of Malone Wealth Ventures, LLC, an investment advisory firm based in California, which provides comprehensive asset management and investment advice to its clients with various strategies. Malone Wealth Ventures, LLC served as a consultant to the Company from April 22, 2025, and received 30,000 shares and 60,000 RSU’s of the Company’s Class B Subordinate Voting Shares (“Class B Shares”) as compensation for its consulting services. Malone Wealth Ventures, LLC currently owns, on behalf of its clients, 829,730 Class B Shares, representing approximately
The Company has also pursued aggressive legal action, including an amended complaint filed against CIBC World Markets, RBC Dominion Securities, and others seeking damages exceeding
In parallel, the Company continues to build shareholder value through initiatives such as its advancement of its Multiple Sclerosis Patented New Chemical Entity asset (see PR July 8 2025), the intention to declare a special dividend of contingent value rights tied to potential litigation settlements (see PR June 13 2025), and strategic private placements to fund growth. The acquisition of GameStop shares represents a further step in deploying capital toward undervalued assets with strong fundamentals, reflecting the Company's disciplined approach to asset management amid its core focus on developing treatments like Lucid-MS for multiple sclerosis.
“The Quantum team and I see the extreme value in GameStop going forward and the deep value the company has with
The Company also announces that it has completed a debt settlement in the amount of US
Malone Wealth Ventures, LLC served as a consultant to the Company from April 22, 2025, and received 30,000 Class B shares and 60,000 RSU’s of the Company as compensation for its consulting services.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.
Forward-Looking Information
This press release contains certain "forward-looking statements" within the meaning of applicable Canadian securities law. Forward-looking statements are frequently characterized by words such as "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements include the Company’s belief that its investment in GameStop represents a strategic opportunity and its expectation of a potential increase in GameStock’s stock price. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors, including the risk that the GameStock stock price may not increase as anticipated, that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
FAQ
What is the size of Quantum BioPharma's (QNTM) investment in GameStop?
How much does Malone Wealth Ventures own in Quantum BioPharma stock?
What is the amount of damages Quantum BioPharma is seeking in its legal action?
How did Quantum BioPharma settle its recent debt?
What compensation did Malone Wealth Ventures receive for consulting services?
